Zhang Qingchuan, Hong Bin, Wu Songhua, Niu Tianli
Department of Urology, Putuo Hospital,, Shanghai University of Traditional Chinese Medicine, No. 164 Lanxi Road, Shanghai, 200062, China,
Tumour Biol. 2015 Apr;36(4):2377-81. doi: 10.1007/s13277-014-2845-5. Epub 2014 Nov 23.
Ginsenoside Rh2 (GRh2) has been reported to have therapeutic effects on some types of cancer, but its effect on prostatic cancer has not been extensively evaluated. Here, we show that GRh2 can substantially inhibit the growth of prostatic cancer in vivo and in vitro. Moreover, the inhibition of the tumor growth appeared to result from a combined inhibitory effect on tumor cell proliferation and tumor cell invasiveness. Further analyses suggest that GRh2 seemed to activate transforming growth factor β (TGFβ) receptor signaling in prostatic cancer cells, which subsequently inhibits cell proliferation and invasion through regulating cell-cycle controllers and (MMPs), respectively. Taken together, our data reveal an essential anti-prostatic cancer effect of GRh2 and demonstrate that this effect is through augment of TGFβ receptor signaling in the prostatic cancer cells. GRh2 thus appears to be a promising therapy for prostatic cancer.
人参皂苷Rh2（GRh2）已被报道对某些类型的癌症具有治疗作用，但其对前列腺癌的作用尚未得到广泛评估。在此，我们表明GRh2可在体内和体外显著抑制前列腺癌的生长。此外，肿瘤生长的抑制似乎是由于对肿瘤细胞增殖和肿瘤细胞侵袭性的联合抑制作用。进一步分析表明，GRh2似乎激活了前列腺癌细胞中的转化生长因子β（TGFβ）受体信号通路，随后分别通过调节细胞周期调控因子和基质金属蛋白酶（MMPs）来抑制细胞增殖和侵袭。综上所述，我们的数据揭示了GRh2对前列腺癌具有重要的抗癌作用，并证明这种作用是通过增强前列腺癌细胞中的TGFβ受体信号通路实现的。因此，GRh2似乎是一种有前景的前列腺癌治疗药物。
